MX356745B - Anticuerpo monoclonal humano contra la proteina vp1 del virus jc. - Google Patents

Anticuerpo monoclonal humano contra la proteina vp1 del virus jc.

Info

Publication number
MX356745B
MX356745B MX2014015850A MX2014015850A MX356745B MX 356745 B MX356745 B MX 356745B MX 2014015850 A MX2014015850 A MX 2014015850A MX 2014015850 A MX2014015850 A MX 2014015850A MX 356745 B MX356745 B MX 356745B
Authority
MX
Mexico
Prior art keywords
virus
protein
monoclonal antibody
jcv
antibody against
Prior art date
Application number
MX2014015850A
Other languages
English (en)
Other versions
MX2014015850A (es
Inventor
Burionii Roberto
Clementi Massimo
Original Assignee
Pomona Ricerca Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pomona Ricerca Srl filed Critical Pomona Ricerca Srl
Publication of MX2014015850A publication Critical patent/MX2014015850A/es
Publication of MX356745B publication Critical patent/MX356745B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a un anticuerpo monoclonal neutralizante humano dirigido contra la proteína VP1 del virus JC, que es el virus responsable de la leucoencefalopatía multifocal progresiva (PML), así como con el uso del mismo en un tratamiento terapéutico o profiláctico de una infección por JCV o de una enfermedad asociada con una infección por JCV, tal como la leucoencefalopatía multifocal progresiva (PML), y el uso del mismo en el diagnóstico de infecciones por JCV o de enfermedades asociadas con infecciones por JCV.
MX2014015850A 2012-06-27 2013-06-26 Anticuerpo monoclonal humano contra la proteina vp1 del virus jc. MX356745B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000570A ITTO20120570A1 (it) 2012-06-27 2012-06-27 Anticorpo monoclonale diretto contro il virus jc
PCT/IB2013/055257 WO2014002035A2 (en) 2012-06-27 2013-06-26 A human monoclonal antibody against the vp1 protein of jc virus

Publications (2)

Publication Number Publication Date
MX2014015850A MX2014015850A (es) 2015-08-20
MX356745B true MX356745B (es) 2018-06-12

Family

ID=46690644

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014015850A MX356745B (es) 2012-06-27 2013-06-26 Anticuerpo monoclonal humano contra la proteina vp1 del virus jc.

Country Status (12)

Country Link
US (1) US10011648B2 (es)
EP (1) EP2867257B1 (es)
JP (1) JP6320375B2 (es)
KR (1) KR102085305B1 (es)
CN (1) CN104520318B (es)
BR (1) BR112014032682B1 (es)
CA (1) CA2877598C (es)
EA (1) EA029346B1 (es)
ES (1) ES2673230T3 (es)
IT (1) ITTO20120570A1 (es)
MX (1) MX356745B (es)
WO (1) WO2014002035A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITTO20120570A1 (it) * 2012-06-27 2013-12-28 Pomona Ricerca Srl Anticorpo monoclonale diretto contro il virus jc
JP6407165B2 (ja) 2012-12-31 2018-10-17 ニューリミューン ホールディング エイジー ポリオーマウイルス関連疾患の治療および防止のための組換えヒト抗体
US9862760B2 (en) * 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
JP2018203632A (ja) * 2017-05-30 2018-12-27 公益財団法人ヒューマンサイエンス振興財団 モノクローナル抗体及び測定キット
CA3083363A1 (en) * 2017-12-01 2019-06-06 Novartis Ag Polyomavirus neutralizing antibodies
CA3142000A1 (en) * 2019-06-19 2020-12-24 Icahn School Of Medicine At Mount Sinai Monoclonal antibodies against jc virus
CN111732654B (zh) * 2020-06-19 2021-05-25 武汉生物制品研究所有限责任公司 一种抗SARS-CoV-2的单克隆抗体1E10
CN118047865A (zh) * 2024-04-15 2024-05-17 北京市农林科学院 一种牛早幼粒细胞白血病蛋白单克隆抗体及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP3767755B2 (ja) * 1995-06-23 2006-04-19 エーザイ株式会社 抗ｊｃウイルス抗体
DE19543553B4 (de) * 1995-11-22 2009-04-09 Deutsches Primatenzentrum Gmbh VP-Antigene des JC-Virus
JP4840792B2 (ja) * 2001-11-22 2011-12-21 独立行政法人科学技術振興機構 ＪＣウイルスａｇｎｏを対象としたＰＭＬの治療
PL2828284T3 (pl) * 2012-03-20 2019-11-29 Biogen Ma Inc Przeciwciała neutralizujące wirus jc
DK2828292T3 (da) * 2012-03-20 2019-01-02 Biogen Ma Inc Jcv-neutraliserende antistoffer
ITTO20120570A1 (it) * 2012-06-27 2013-12-28 Pomona Ricerca Srl Anticorpo monoclonale diretto contro il virus jc
JP6407165B2 (ja) * 2012-12-31 2018-10-17 ニューリミューン ホールディング エイジー ポリオーマウイルス関連疾患の治療および防止のための組換えヒト抗体

Also Published As

Publication number Publication date
US20150191530A1 (en) 2015-07-09
JP6320375B2 (ja) 2018-05-09
EA029346B1 (ru) 2018-03-30
EP2867257A2 (en) 2015-05-06
EA201590111A1 (ru) 2015-04-30
MX2014015850A (es) 2015-08-20
KR102085305B1 (ko) 2020-03-05
CN104520318A (zh) 2015-04-15
CA2877598C (en) 2021-10-19
EP2867257B1 (en) 2018-03-14
CA2877598A1 (en) 2014-01-03
BR112014032682A2 (pt) 2017-08-01
CN104520318B (zh) 2017-12-15
ES2673230T3 (es) 2018-06-20
KR20150023893A (ko) 2015-03-05
WO2014002035A3 (en) 2014-02-27
US10011648B2 (en) 2018-07-03
WO2014002035A2 (en) 2014-01-03
ITTO20120570A1 (it) 2013-12-28
BR112014032682B1 (pt) 2020-10-27
JP2015524389A (ja) 2015-08-24

Similar Documents

Publication Publication Date Title
MX356745B (es) Anticuerpo monoclonal humano contra la proteina vp1 del virus jc.
MX2019012233A (es) Anticuerpos anti-sirpa.
GEP20217263B (en) Anti-cd27 antibodies
PH12017500296B1 (en) Anti-tigit antibodies
MX2022005253A (es) Anticuerpos neutralizantes de poliomavirus.
IN2014DN07149A (es)
EA201390060A1 (ru) Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
PH12015501558B1 (en) Human antibodies to respiratory syncytial virus f protein and methods of use thereof
EA201300558A1 (ru) Соединения и способы для купирования боли
EA032929B1 (ru) Нейтрализующее вирус иммунодефицита человека антитело и способы его применения
GT201200318A (es) Anticuerpos hacia gdf8 humano
WO2012021786A3 (en) Anti-hemagglutinin antibody compositions and methods of use thereof
WO2014176128A3 (en) Compositions and methods for the therapy and diagnosis of influenza
EA201490004A1 (ru) Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
WO2013169864A3 (en) TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE
EA201391616A1 (ru) Применение тиазолидных соединений для предотвращения и лечения вирусных заболеваний, рака и заболеваний, вызванных внутриклеточными инфекциями
EP2955195A4 (en) ANTI-SEMAPHORIN-3A ANTIBODY AND TREATMENT OF ALZHEIMER AND INFLAMMATORY IMMUNE DISEASES THEREWITH
PH12015500114A1 (en) HUMAN ANTIBODIES TO GFRa3 AND METHODS OF USE THEREOF
EA201591973A1 (ru) Антитела человека, связывающиеся с g-белком rsv
EA201300136A1 (ru) Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида
MY170725A (en) Dengue-virus serotype neutralizing antibodies
MX2013010367A (es) Composiciones y metodos para la terapia y diagnostico de influenza.
EA201592242A1 (ru) Производные пиридона для лечения вирусных инфекций и других заболеваний

Legal Events

Date Code Title Description
HH Correction or change in general
HH Correction or change in general
FG Grant or registration